SGCB and heart failure: Vericiguat was the first sGC stimulator to be marketed as of 2021, for patients with symptomatic chronic heart failure accompanied by an ejection fraction of 45%, to reduce the risk of cardiovascular death and heart failure hospitalization after heart failure hospitalization or the need for outpatient IV diuretics (Markham and Duggan, 2021).